(Q43206347)

English

Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia.

scientific article published in February 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20038234%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20038234%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

Alberto Ballestrero

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20038234%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

Angelo M Carella

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20038234%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Anna Garuti

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20038234%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Gabriella Cirmena

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20038234%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Gioacchino Catania

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20038234%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Ilaria Rocco

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20038234%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Claudia Palermo

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20038234%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Gianmatteo Pica

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20038234%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Ivana Pierri

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20038234%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Maurizio Miglino

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20038234%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Marco Gobbi

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20038234%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Franco Patrone

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20038234%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 February 2010

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20038234%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20038234%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

51

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20038234%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20038234%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

275-278

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20038234%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428190903503446

21 January 2018

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428190903503446

21 January 2018

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428190903503446

21 January 2018

Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha

1 reference

https://api.crossref.org/works/10.3109%2F10428190903503446

21 January 2018

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment

1 reference

https://api.crossref.org/works/10.3109%2F10428190903503446

21 January 2018

Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.3109%2F10428190903503446

21 January 2018

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.3109%2F10428190903503446

21 January 2018

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428190903503446

21 January 2018

Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib

1 reference

https://api.crossref.org/works/10.3109%2F10428190903503446

21 January 2018

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

1 reference

https://api.crossref.org/works/10.3109%2F10428190903503446

21 January 2018

Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.3109%2F10428190903503446

21 January 2018

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

1 reference

https://api.crossref.org/works/10.3109%2F10428190903503446

21 January 2018

Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428190903503446

21 January 2018

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.

1 reference

https://api.crossref.org/works/10.3109%2F10428190903503446

21 January 2018

Chronic myeloid leukemia: an historical perspective

1 reference

https://api.crossref.org/works/10.3109%2F10428190903503446

21 January 2018

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis

1 reference

https://api.crossref.org/works/10.3109%2F10428190903503446

21 January 2018

ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party o

1 reference

https://api.crossref.org/works/10.3109%2F10428190903503446

21 January 2018

Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)

1 reference

https://api.crossref.org/works/10.3109%2F10428190903503446

21 January 2018

Identifiers

10.3109/10428190903503446

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20038234%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20038234%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43206347&oldid=1623226044"